[NOTICE: This consolidated financial summary is a translation of the Japanese original for reference purposes only, and in the event of any discrepancy, the Japanese original shall prevail.]

# Consolidated Financial Summary under Japanese GAAP for the Fiscal Year Ended September 30, 2026

November 13, 2026

Company Name: Amvis Holdings, Inc.
Stock Exchange Listing: Tokyo
Code Number: 7071
URL: https://www.amvis.com/en/
Representative: Keiichi Shibahara, Representative Director and CEO
Inquiries: Shingo Yamaguchi, Director
TEL: +81-3-6262-5105
General Meeting of Shareholders Date: December 18, 2026
Dividend Payment Date: December 21, 2026
Securities Report Issue Date: December 17, 2026
Supplementary Information for Financial Statements: Yes
Explanatory Meeting to Be held: Yes (for institutional investors, analysts, and individual investors)

(Amounts of less than one million yen are truncated)

## 1. Consolidated Financial Results for the Fiscal Year Ended September 30, 2026

(1) Consolidated Operating Results (% represents the change from the previous fiscal year)

| | Net Sales | | EBITDA | | Operating Profit | | Ordinary Profit | | Profit Attributable to Owners of Parent | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fiscal Year Ended | million yen | % | million yen | % | million yen | % | million yen | % | million yen | % |
| September 30, 2026 | 50,121 | 1.9 | 7,471 | (16.7) | 4,037 | (34.5) | 4,013 | (36.7) | 1,277 | (65.1) |
| September 30, 2025 | 49,174 | 15.8 | 8,966 | (28.2) | 6,162 | (41.9) | 6,343 | (39.9) | 3,660 | (50.8) |

Notes
1. Comprehensive Income
   Fiscal year September 30, 2026: 1,292 million yen / (64.6) %
   Fiscal year September 30, 2025: 3,647 million yen / (51.0) %
2. EBITDA = Operating profit + Depreciation + Amortization of goodwill + Share-based compensation expenses

| | Earnings per Share | Diluted Earnings per Share | Return on Equity | Ratio of Ordinary Profit to Total Assets | Ratio of Operating Profit to Net Sales |
|---|---|---|---|---|---|
| Fiscal Year Ended | yen | yen | % | % | % |
| September 30, 2026 | 13.05 | 13.04 | 3.5 | 5.0 | 8.1 |
| September 30, 2025 | 37.52 | 37.51 | 10.6 | 8.1 | 12.5 |

Reference: Profit or loss on equity method investments:
Fiscal year ended September 30, 2026: - million yen
Fiscal year ended September 30, 2025: - million yen

(2) Consolidated Financial Position

| | Total Assets | Total Net Assets | Shareholders' Equity Ratio | Net Assets per Share |
|---|---|---|---|---|
| As of | million yen | million yen | % | yen |
| September 30, 2026 | 76,214 | 37,386 | 49.0 | 380.54 |
| September 30, 2025 | 83,947 | 36,132 | 43.0 | 370.46 |

Reference: Shareholders' equity:
As of September 30, 2026: 37,313 million yen
As of September 30, 2025: 36,132 million yen

(3) Consolidated Cash Flow

| | Net cash provided by (used in) operating activities | Net cash provided by (used in) investing activities | Net cash provided by (used in) financing activities | Cash and cash equivalents at the end of period |
|---|---|---|---|---|
| Fiscal Year ended | million yen | million yen | million yen | million yen |
| September 30, 2026 | 6,141 | (3,890) | (9,883) | 3,201 |
| September 30, 2025 | 6,025 | (10,427) | 6,365 | 10,833 |

**2. Dividends on Common Stock**

| | Dividends per Share | | | | | Total Dividends (annual) | Payout Ratio (consolidated) | Dividends to Net Assets (consolidated) |
|---|---|---|---|---|---|---|---|---|
| | 1st quarter end | 2nd quarter end | 3rd quarter end | Fiscal year end | Annual | | | |
| Fiscal Year Ended | yen | yen | yen | yen | yen | million yen | % | % |
| September 30, 2025 | — | 0.00 | — | 4.00 | 4.00 | 390 | 10.7 | 1.1 |
| September 30, 2026 | — | 0.00 | — | 4.00 | 4.00 | 392 | 30.7 | 1.1 |
| Fiscal Year Ending September 30, 2027 | — | 0.00 | — | 4.00 | 4.00 | | 7.4 | |

**3. Consolidated Earnings Forecasts for the Fiscal Year Ending September 30, 2027**

(% represents the change from the previous fiscal year)

| | Net Sales | | EBITDA | | Operating Profit | | Ordinary Profit | | Profit Attributable to Owners of Parent | | Earnings per Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| | million yen | % | million yen | % | million yen | % | million yen | % | million yen | % | yen |
| Fiscal Year Ending September 30, 2027 | 35,600 | (29.0) | 3,700 | (50.5) | 1,100 | (72.8) | 900 | (77.6) | 5,300 | 315.0 | 54.14 |

Notes

1. Significant changes in the scope of consolidation: Yes
   Newly included: None
   Excluded:1 company
   (Company name) Midori Co., Ltd.
   For details, please refer to the attachment on page 15 entitled "3. Consolidated Financial Statements and Principal Notes, (5) Notes Regarding Consolidated Financial Statements (Changes in the Scope of Consolidation or Application of the Equity Method)."

2. Changes in accounting policies, accounting estimates and Restatement of correction

(A) Changes in accounting policies due to revision of accounting standards: No

(B) Other changes in accounting policies: No

(C) Changes in accounting estimates: No

(D) Restatement of corrections: No

3. Number of shares outstanding (common shares)

(A) Total shares outstanding including treasury shares

| | |
|---|---|
| As of September 30, 2026 | 98,112,000 shares |
| As of September 30, 2025 | 98,112,000 shares |

(B) Treasury shares

| | |
|---|---|
| As of September 30, 2026 | 58,857 shares |
| As of September 30, 2025 | 578,157 shares |

(C) Average outstanding shares

| | |
|---|---|
| Fiscal Year Ended September 30, 2026 | 97,887,239 shares |
| Fiscal Year Ended September 30, 2025 | 97,559,825 shares |

Reference: Summary of the Non-consolidated Financial Results

**1. Non-consolidated Financial Results for the Fiscal Year Ended September 30, 2026**

(1) Non-consolidated Operating Results (% represents the change from the previous fiscal year)

| | Operating Revenue | | Operating Profit | | Ordinary Profit | | Net Profit | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Year Ended | million yen | % | million yen | % | million yen | % | million yen | % |
| September 30, 2026 | 9,331 | 13.1 | 2,730 | 14.4 | 2,440 | 7.1 | 2,273 | 6.1 |
| September 30, 2025 | 8,248 | (12.3) | 2,387 | (53.5) | 2,279 | (55.9) | 2,142 | (58.2) |

| | Earnings per Share | Diluted Earnings per Share |
|---|---|---|
| Fiscal Year Ended | yen | yen |
| September 30, 2026 | 23.23 | 23.23 |
| September 30, 2025 | 21.97 | 21.96 |

(2) Non-consolidated Financial Position

| | Total Assets | Total Net Assets | Shareholders' Equity Ratio | Net Assets per Share |
|---|---|---|---|---|
| As of | million yen | million yen | % | yen |
| September 30, 2026 | 56,311 | 23,191 | 41.1 | 235.77 |
| September 30, 2025 | 57,783 | 20,956 | 36.3 | 214.86 |

Reference: Shareholders' equity:
As of September 30, 2026: 23,118 million yen
As of September 30, 2025: 20,956 million yen

This financial summary is not subject to audit by a certified public accountant or audit firm.

Notes for using earnings forecasts in this report and others

Disclaimer regarding forward-looking information including appropriate use of forecast financial results

This report contains forward-looking statements, such as earnings forecasts, regarding the intent, beliefs and current expectations of Amvis Holdings, Inc. (hereinafter referred to as the "Company") and its management with respect to the expected financial position and results of operations of the Company. Actual performance and results may differ from those forecasts due to various factors.

**Table of Contents of Appendix**

1. Consolidated Operating Results ..... 5
(1) Overview of Consolidated Operating Results ..... 5
(2) Overview of Financial Position ..... 6
(3) Overview of Cash Flows ..... 6
(4) Forecast ..... 7
2. Basic Concept Regarding the Selection of Accounting Standards ..... 7
3. Consolidated Financial Statements and Principal Notes ..... 8
(1) Consolidated Balance Sheets ..... 8
(2) Consolidated Statements of Income and Consolidated Statements of Comprehensive Income ..... 10
Consolidated Statements of Income ..... 10
Consolidated Statements of Comprehensive Income ..... 11
(3) Consolidated Statements of Changes in Net Assets ..... 12
(4) Consolidated Statements of Cash Flows ..... 13
(5) Notes Regarding Consolidated Financial Statements ..... 15
(Going Concern Assumption) ..... 15
(Change in Scope of Consolidation or Equity Method) ..... 15
(Changes in Accounting Policies) ..... 15
(Segment Information) ..... 15
(Per Share Information) ..... 17
(Significant Subsequent Events) ..... 18

1. Consolidated Operating Results

(1) Overview of Consolidated Operating Results

The Group has set forth the vision of becoming “the world’s most exciting medical and healthcare company,” aiming to create second and third core businesses following the Ishinkan business and to become a company that will continue to prosper for the next 100 years.

During the current consolidated fiscal year, the Group opened 9 new facilities under the Ishinkan business (Saitama: 1, Chiba: 1, Tokyo: 3, Kanagawa: 2, Mie: 1, Osaka: 1), while transferring the operations of Ishinkan Kurashiki. In addition, to prioritize the allocation of management resources to the Tokyo metropolitan and East Japan areas, and to strengthen the financial base and expand capacity for growth investment, the Group decided to transfer the business related to 47 facilities, primarily in the West Japan area. Going forward, the Group will strive for sustainable growth and improved profitability through facility openings based on detailed marketing and by increasing the occupancy rates of existing facilities.

In the comprehensive medical support business, the Group has leveraged the expertise and know-how accumulated through the operation of Ishinkan facilities and has steadily built a track record of providing management support services to medical institutions during the current consolidated fiscal year. Going forward, the Group will expand its initiatives beyond local and depopulated areas to provide comprehensive management support to a wide range of medical institutions, including general hospitals and community-based hospitals. The Group will continue to be a hungry challenger, boldly questioning conventional practices and exploring innovative solutions to create essential and fundamental value, while envisioning an ambitious future. As a result, the operating results for the current consolidated fiscal year are as follows.

[Consolidated Financial Results for the Fiscal Year Ended September 30, 2026]

(Unit: million yen)

| | Fiscal Year Ended September 30, 2025 | Fiscal Year Ended September 30, 2026 | YoY Change | YoY(%) |
|---|---|---|---|---|
| Net Sales | 49,174 | 50,121 | 946 | 1.9% |
| EBITDA | 8,966 | 7,471 | (1,495) | (16.7%) |
| Operating Profit | 6,162 | 4,037 | (2,124) | (34.5%) |
| Ordinary Profit | 6,343 | 4,013 | (2,329) | (36.7%) |
| Profit Attributable to Owners of Parent | 3,660 | 1,277 | (2,383) | (65.1%) |

(Note) EBITDA = Operating Profit + Depreciation + Amortization of goodwill + Share-based compensation expenses

Operating results by segment are as follows.

Note that from the beginning of the current consolidated fiscal year, the Group has changed its reportable segments from a single segment to two segments: "Ishinkan" and "Comprehensive Medical Support," as it was determined that this classification better reflects the Group's management reality from the perspectives of reallocation of management resources, the actual state of the management control system, and future growth strategies. The following year-on-year comparisons are based on figures for the previous consolidated fiscal year that have been reclassified into the new segment categories. For details, please refer to "3. Consolidated Financial Statements and Principal Notes, Notes."

Operating Results by Segment for the Current Consolidated Fiscal Year

(Unit: million yen)

| Segment | Item | Fiscal year ended September 30, 2025 | Fiscal year ended September 30, 2026 | YoY Change | YoY(%) |
|---|---|---|---|---|---|
| Ishinkan | Net sales | 48,620 | 48,927 | 306 | 0.6 % |
| | Segment profit | 5,925 | 3,264 | (2,660) | (44.9) % |
| Comprehensive medical support | Net sales | 553 | 1,195 | 641 | 115.9 % |
| | Segment profit | 237 | 773 | 535 | 225.8 % |

(Note) 1. Net sales represent net sales for each segment.
2. Segment profit represents operating profit for each segment.

(i) Ishinkan Business

In the Ishinkan business, despite a temporary decline in facility occupancy rates due to the impact of responding to the Special Investigation Committee and a decrease in unit compensation prices following the medical service fee revision implemented in June 2026, net sales were 48,927 million yen (up 0.6% year-on-year) due to factors such as the progress in the ramp-up of facilities opened in the previous fiscal year.

On the other hand, the gross profit margin declined due to the impact of the decrease in unit compensation prices resulting from the medical service fee revision, as well as proactive staffing for new facility openings and an increase in personnel expenses aimed at securing human resources, resulting in a segment profit of 3,264 million yen (down 44.9% year-on-year).

(ii) Comprehensive Medical Support Business

In the Comprehensive Medical Support business, net sales were 1,195 million yen (up 115.9% year-on-year) due to an increase of 4 medical institutions receiving management support and the expansion of services provided to existing support recipients.
In addition, driven by the increase in net sales, segment profit was 773 million yen (up 225.8% year-on-year).

As a result, the Group's performance for the current consolidated fiscal year was as follows: net sales of 50,121 million yen (up 1.9% year-on-year), operating profit of 4,037 million yen (down 34.5% year-on-year), ordinary profit of 4,013 million yen (down 36.7% year-on-year), and profit attributable to owners of parent of 1,277 million yen (down 65.1% year-on-year).

(2) Overview of Financial Position

Assets, Liabilities and Net Assets

(Assets)

Total assets as of the end of the current consolidated fiscal year were 76,214 million yen, a decrease of 7,732 million yen from the end of the previous consolidated fiscal year. This was mainly due to a decrease of 7,631 million yen in cash and deposits due to the repayment of borrowings.

(Liabilities)

Total liabilities as of the end of the current consolidated fiscal year were 38,827 million yen, a decrease of 8,988 million yen from the end of the previous consolidated fiscal year. This was mainly due to a decrease of 9,285 million yen in borrowings due to repayments.

(Net assets)

Total net assets as of the end of the current consolidated fiscal year were 37,386 million yen, an increase of 1,254 million yen from the end of the previous consolidated fiscal year. This was mainly due to an increase in retained earnings from 1,277 million yen in profit attributable to owners of parent, as well as a decrease of 744 million yen in treasury shares due to the disposal of treasury shares in connection with the granting of restricted stock.

(3) Overview of Cash Flows

Cash and cash equivalents as of the end of the current consolidated fiscal year stood at 3,201 million yen, a decrease of 7,631 million yen from the end of the previous consolidated fiscal year. Cash flows for the period and the factors contributing to increases or decreases in cash flows are as follows.

(Cash flows from operating activities)

Net cash provided by operating activities was 6,141 million yen (compared to 6,025 million yen provided in the previous fiscal year). This was mainly due to 1,878 million yen in profit before income taxes and 3,268 million yen in depreciation, despite 1,361 million yen in income taxes paid.

(Cash flows from investing activities)

Net cash used in investing activities was 3,890 million yen (compared to 10,427 million yen used in the previous fiscal year). This was mainly due to 3,889 million yen in expenditures for the purchase of property, plant and equipment in connection with the opening of new facilities.

(Cash flows from financing activities)

Net cash used in financing activities was 9,883 million yen (compared to 6,365 million yen provided in the previous fiscal year). This was mainly due to expenditures of 5,493 million yen for the repayment of long-term borrowings and a net decrease of 7,699 million yen in short-term borrowings, while proceeds of 3,907 million yen were generated from long-term borrowings in connection with the opening of new facilities.

(4) Forecast

In the Ishinkan business for the next fiscal year, net sales and segment profit are expected to fall below the current fiscal year's levels, due to the full-year impact of the decline in unit price resulting from the revision of medical treatment fees, as well as the transfer of businesses related to 47 facilities mainly in the Western Japan area. Although the occupancy rate is expected to remain sluggish in the first half due to staff shortages resulting from the optimization of staffing in the current fiscal year, a gradual recovery is expected in the second half due to new hires mainly in April. We will continue to work on improving profitability while maintaining service quality, by promoting improvements in facility occupancy rates and optimizing staffing in accordance with occupancy conditions.

In the Comprehensive Medical Support business, backed by a rich pipeline of candidate support projects, we will expand our support team through additional hires and increase the number of partner medical institutions, and net sales and segment profit are expected to exceed the current fiscal year's levels.

Regarding consolidated results, net sales and operating profit are expected to fall below the current fiscal year's levels due to the decrease in revenue and profit in the Ishinkan business. On the other hand, profit attributable to owners of parent is expected to significantly exceed the current fiscal year's level, as a gain on the transfer of the Ishinkan Western Japan area business is expected to be recorded as extraordinary income.

In addition, the Group places greater emphasis on EBITDA as one of its key management indicators to assess profitability excluding the effects of depreciation, amortization and other non-cash expenses.

Based on this premise, the consolidated financial results forecast for the next fiscal year is as follows: Net sales of 35,600 million yen, EBITDA of 3,700 million yen, Operating profit of 1,100 million yen, Ordinary profit of 900 million yen, and Profit attributable to owners of parent of 5,300 million yen.

Please note that the above earnings forecasts are based on information available at present and contain uncertain factors. Actual results may differ due to changes in business conditions and other factors.

2. Basic Concept Regarding the Selection of Accounting Standards

The Group applies Japanese GAAP, taking into account comparability with other companies in the same industry in Japan.

3. Consolidated Financial Statements and Principal Notes

(1) Consolidated Balance Sheets

(Unit: million yen)

| | As of September 30, 2025 | As of September 30, 2026 |
|---|---|---|
| Assets | | |
| Current assets | | |
| Cash and deposits | 10,833 | 3,201 |
| Accounts receivable | 9,191 | 8,613 |
| Inventories | 30 | 58 |
| Other | 1,855 | 1,694 |
| Allowance for doubtful accounts | (171) | (211) |
| Total current assets | 21,738 | 13,357 |
| Non-current assets | | |
| Property, plant and equipment | | |
| Buildings and structures, net | 43,979 | 43,157 |
| Machinery, equipment and vehicles, net | 4 | 2 |
| Tools, furniture and fixtures, net | 202 | 208 |
| Leased assets, net | 7,914 | 8,931 |
| Land | 2,471 | 3,275 |
| Construction in progress | 2,592 | 1,428 |
| Total property, plant and equipment | 57,165 | 57,004 |
| Intangible assets | | |
| Other | 185 | 166 |
| Total intangible assets | 185 | 166 |
| Investments and other assets | | |
| Leasehold and guarantee deposits | 3,570 | 3,595 |
| Deferred tax assets | 851 | 1,652 |
| Other | 436 | 438 |
| Total investments and other assets | 4,857 | 5,685 |
| Total non-current assets | 62,208 | 62,857 |
| Total assets | 83,947 | 76,214 |

(Unit: million yen)

| | As of September 30, 2025 | As of September 30, 2026 |
|---|---|---|
| Liabilities | | |
| Current liabilities | | |
| Accounts payable | 149 | 153 |
| Short-Term borrowings | 7,699 | - |
| Current portion of long-term borrowings | 4,763 | 5,199 |
| Lease obligations | 202 | 240 |
| Accounts payable - other and accrued expenses | 3,748 | 3,117 |
| Income taxes payable | 433 | 482 |
| Provision for bonuses | 1,310 | 1,177 |
| Provision for litigation losses | - | 13 |
| Other | 1,137 | 823 |
| Total current liabilities | 19,444 | 11,206 |
| Non-current liabilities | | |
| Long-term borrowings | 19,277 | 17,256 |
| Lease obligations | 8,210 | 9,300 |
| Provision for litigation losses | 11 | - |
| Asset retirement obligations | 639 | 659 |
| Net defined benefit liability | 66 | 70 |
| Other | 164 | 334 |
| Total non-current liabilities | 28,369 | 27,620 |
| Total liabilities | 47,814 | 38,827 |
| Net assets | | |
| Shareholders' equity | | |
| Share capital | 66 | 66 |
| Capital surplus | 11,641 | 11,175 |
| Retained earnings | 25,187 | 26,074 |
| Treasury shares | (750) | (5) |
| Total shareholders' equity | 36,145 | 37,310 |
| Accumulated other comprehensive income | | |
| Remeasurements of defined benefit plans | (12) | 2 |
| Total accumulated other comprehensive income | (12) | 2 |
| Share acquisition rights | - | 73 |
| Total net assets | 36,132 | 37,386 |
| Total liabilities and net assets | 83,947 | 76,214 |

(2) Consolidated Statements of Income and Consolidated Statements of Comprehensive Income

[Consolidated Statements of Income]

(Unit: million yen)

| | Fiscal year ended September 30, 2025 | Fiscal year ended September 30, 2026 |
|---|---|---|
| Net sales | 49,174 | 50,121 |
| Cost of sales | 34,385 | 37,266 |
| Gross profit | 14,789 | 12,854 |
| Selling, general and administrative expenses | 8,626 | 8,816 |
| Operating profit | 6,162 | 4,037 |
| Non-operating income | | |
| Subsidy income | 500 | 572 |
| Recovery of written-off receivables | 2 | 1 |
| Gain on sale of investments | 149 | - |
| Miscellaneous income | 109 | 150 |
| Total non-operating income | 761 | 724 |
| Non-operating expenses | | |
| Interest expenses | 563 | 678 |
| Miscellaneous loss | 16 | 70 |
| Total non-operating expenses | 580 | 748 |
| Ordinary profit | 6,343 | 4,013 |
| Extraordinary Income | | |
| Insurance claim income | 50 | - |
| Gain on transfer of business | - | 34 |
| Total Extraordinary Income | 50 | 34 |
| Extraordinary losses | | |
| Impairment losses | - | 2,142 |
| Loss on retirement of non-current assets | - | 14 |
| Special investigation expenses | 650 | - |
| Provision for loss on litigation | 11 | 13 |
| Others | 46 | - |
| Total extraordinary losses | 708 | 2,170 |
| Profit before income taxes | 5,685 | 1,878 |
| Income taxes | 2,077 | 1,410 |
| Income taxes-deferred | (51) | (809) |
| Total income taxes | 2,025 | 601 |
| Profit | 3,660 | 1,277 |
| Profit attributable to non-controlling interests | - | - |
| Profit attributable to owners of parent | 3,660 | 1,277 |

[Consolidated Statements of Comprehensive Income]

(Unit: million yen)

| | Fiscal year ended September 30, 2025 | Fiscal year ended September 30, 2026 |
|---|---|---|
| Profit | 3,660 | 1,277 |
| Other comprehensive income | | |
| Remeasurements of defined benefit plans | (12) | 15 |
| Total other comprehensive income | (12) | 15 |
| Comprehensive income | 3,647 | 1,292 |
| (Details) | | |
| Attributable to owners of parent | 3,647 | 1,292 |
| Attributable to non-controlling interests | - | - |

(3) Consolidated Statements of Changes in Net Assets

Fiscal year ended September 30, 2025

(Unit: million yen)

| | Shareholder's Equity | | | | | Accumulated Other Comprehensive Income | | Share acquisition rights | Total Net Assets |
|---|---|---|---|---|---|---|---|---|---|
| | Share Capital | Capital Surplus | Retained Earnings | Treasury Shares | Total Shareholders' Equity | Remeasurements of Defined Benefit Plans | Total Accumulated Other Comprehensive Income | | |
| Balance at the beginning of current period | 65 | 11,701 | 21,918 | (472) | 33,212 | (0) | (0) | - | 33,212 |
| Changes during the period | | | | | | | | | |
| Dividends from surplus | | | (391) | | (391) | | | | (391) |
| Issuance of new shares | 1 | 1 | | | 3 | | | | 3 |
| Profit attributable to owners of parent | | | 3,660 | | 3,660 | | | | 3,660 |
| Acquisition of treasury shares | | | | (389) | (389) | | | | (389) |
| Restricted stock | | (61) | | 110 | 49 | | | | 49 |
| Net changes of items other than shareholders' equity | | | | | | (12) | (12) | - | (12) |
| Total changes during the period | 1 | (59) | 3,268 | (278) | 2,932 | (12) | (12) | - | 2,920 |
| Balance at the end of current period | 66 | 11,641 | 25,187 | (750) | 36,145 | (12) | (12) | - | 36,132 |

Fiscal year ended September 30, 2026

(Unit: million yen)

| | Shareholder's Equity | | | | | Accumulated Other Comprehensive Income | | Share acquisition rights | Total Net Assets |
|---|---|---|---|---|---|---|---|---|---|
| | Share Capital | Capital Surplus | Retained Earnings | Treasury Shares | Total Shareholders' Equity | Remeasurements of Defined Benefit Plans | Total Accumulated Other Comprehensive Income | | |
| Balance at the beginning of current period | 66 | 11,641 | 25,187 | (750) | 36,145 | (12) | (12) | | 36,132 |
| Changes during the period | | | | | | | | | |
| Dividends from surplus | | | (390) | | (390) | | | | (390) |
| Profit attributable to owners of parent | | | 1,277 | | 1,277 | | | | 1,277 |
| Restricted stock | | (466) | | 744 | 278 | | | | 278 |
| Net changes of items other than shareholders' equity | | | | | | 15 | 15 | 73 | 88 |
| Total changes during the period | - | (466) | 886 | 744 | 1,165 | 15 | 15 | 73 | 1,254 |
| Balance at the end of current period | 66 | 11,175 | 26,074 | (5) | 37,310 | 2 | 2 | 73 | 37,386 |

(4) Consolidated Statements of Cash Flows

(Unit: million yen)

| | Fiscal year ended September 30, 2025 | Fiscal year ended September 30, 2026 |
|---|---|---|
| Cash flows from operating activities | | |
| Profit before income taxes | 5,685 | 1,878 |
| Loss (Gain) on transfer of business | 46 | (34) |
| Insurance claim income | (50) | - |
| Loss (Gain) on sale of investments | (149) | - |
| Depreciation | 2,753 | 3,268 |
| Impairment losses | | 2,142 |
| Amortization of goodwill | 17 | 23 |
| Increase (decrease) in provision for bonuses | 288 | (133) |
| Increase (decrease) in allowance for doubtful accounts | 109 | 39 |
| Interest income | (15) | (21) |
| Interest expenses | 563 | 678 |
| Subsidy income | (500) | (572) |
| Decrease (increase) in accounts receivable | (731) | 577 |
| Decrease (increase) in inventories | (6) | (28) |
| Decrease (increase) in other assets | (479) | 544 |
| Increase (decrease) in accounts payable | 26 | 3 |
| Increase (decrease) in accounts payable - other and accrued expenses | 1,163 | (643) |
| Increase (decrease) in other liabilities | 825 | (145) |
| Other, net | 12 | 16 |
| Subtotal | 9,561 | 7,593 |
| Interest and dividends received | 20 | 19 |
| Interest paid | (578) | (681) |
| Proceeds from subsidy | 500 | 572 |
| Proceeds from insurance income | 50 | - |
| Income taxes paid | (3,528) | (1,361) |
| Net cash provided by (used in) operating activities | 6,025 | 6,141 |
| Cash flows from investing activities | | |
| Purchase of property, plant and equipment | (10,407) | (3,889) |
| Purchase of intangible assets | (17) | (12) |
| Proceeds from sale of businesses | 360 | 45 |
| Payments for acquisition of business | (115) | - |
| Payments of leasehold and guarantee deposits | (443) | (136) |
| Proceeds from refund of leasehold and guarantee deposits | 40 | 45 |
| Other, net | 156 | 56 |
| Net cash provided by (used in) investing activities | (10,427) | (3,890) |
| Cash flows from financing activities | | |
| Net increase (decrease) in short-term borrowings | 4,366 | (7,699) |
| Proceeds from long-term borrowings | 7,613 | 3,907 |
| Repayments of long-term borrowings | (4,639) | (5,493) |
| Repayments of lease obligations | (191) | (217) |
| Proceeds from issuance of share acquisition rights | - | 10 |
| Dividends paid | (391) | (390) |
| Purchase of treasury shares | (390) | - |

| | | |
|---|---|---|
| Net cash provided by (used in) financing activities | 6,365 | (9,883) |
| Net increase (decrease) in cash and cash equivalents | 1,964 | (7,631) |
| Cash and cash equivalents at the beginning of period | 8,868 | 10,833 |
| Cash and cash equivalents at the end of period | 10,833 | 3,201 |

(5) Notes Regarding Consolidated Financial Statements

(Going Concern Assumption)

Not applicable.

(Change in Scope of Consolidation or Equity Method)

(Significant change in scope of consolidation)

Midori Co., Ltd., which was a consolidated subsidiary in the previous fiscal year, has been excluded from the scope of consolidation due to the completion of its liquidation during the current fiscal year.

(Changes in Accounting Policies)

Not applicable.

(Segment Information)

1. Overview of reportable segments

The Company's reportable segments are components of the Company for which separate financial information is available and which are subject to regular review by the Board of Directors for the purpose of making decisions about the allocation of resources and assessing performance.

The Group has two reportable segments: the "Ishinkan" business, which operates facilities that organically combine home-based services such as "visiting nursing," "visiting care," and "in-home long-term care support" with facility-based services such as "paid nursing homes," and the "Comprehensive Medical Support" business, which provides comprehensive management support for medical institutions and nursing care facilities.

2. Calculation method for sales, profit or loss, assets, liabilities, and other items for each reportable segment

The accounting methods for the reported business segments are consistent with the accounting policies adopted for the preparation of the financial statements.

3. Information regarding sales, profit or loss, assets, liabilities, and other items for each reportable segment, and disaggregated revenue information

Fiscal year ended September 30, 2025

(Unit: million yen)

| | Reportable segments | | | Adjustment (Note 1) | Amounts recorded in consolidated financial statements (Note 2) |
|---|---|---|---|---|---|
| | Ishinkan | Comprehensive Medical Support | Total | | |
| Net sales | | | | | |
| Sales to external customers | 48,620 | 553 | 49,174 | - | 49,174 |
| Intersegment internal sales or transfers | - | - | - | - | - |
| Total | 48,620 | 553 | 49,174 | - | 49,174 |
| Segment profit | 5,805 | 237 | 6,162 | - | 6,162 |
| Segment assets | 78,359 | 2,610 | 80,970 | 2,976 | 83,947 |
| Other items | | | | | |
| Depreciation | 2,744 | - | 2,744 | 6 | 2,750 |
| Amortization of goodwill | 17 | - | 17 | - | 17 |
| Impairment losses | - | - | - | - | - |
| Provision for allowance for doubtful accounts (△ indicates reversal of allowance for doubtful accounts) | 27 | 88 | 115 | - | 115 |

| | | | | | |
|---|---|---|---|---|---|
| Increase in property, plant and equipment and intangible assets | 10,357 | - | 10,357 | - | 10,357 |

(Notes)

1. The adjustment of 2,976 million yen to segment assets represents corporate assets that have not been allocated to any of the reportable segments.
2. Segment profit is reconciled to operating profit as presented in the consolidated statement of income.

Fiscal year ended September 30, 2026

(Unit: million yen)

| | Reportable segments | | | Adjustment (Note 1) | Amounts recorded in consolidated financial statements (Note 2) |
|---|---|---|---|---|---|
| | Ishinkan | Comprehensive Medical Support | Total | | |
| Net sales | | | | | |
| Sales to external customers | 48,927 | 1,193 | 50,121 | - | 50,121 |
| Intersegment internal sales or transfers | - | 2 | 2 | (2) | - |
| Total | 48,927 | 1,195 | 50,123 | (2) | 50,121 |
| Segment profit | 3,264 | 773 | 4,037 | - | 4,037 |
| Segment assets | 70,937 | 2,686 | 73,624 | 2,590 | 76,214 |
| Other items | | | | | |
| Depreciation | 3,229 | 33 | 3,262 | 5 | 3,268 |
| Amortization of goodwill | 23 | - | 23 | - | 23 |
| Impairment losses | 2,142 | - | 2,142 | - | 2,142 |
| Provision for allowance for doubtful accounts (△ indicates reversal of allowance for doubtful accounts) | 37 | 29 | 66 | - | 66 |
| Increase in property, plant and equipment and intangible assets | 3,070 | 832 | 3,902 | 4 | 3,907 |

(Notes)

1. The adjustment of 2,590 million yen to segment assets represents corporate assets that have not been allocated to any of the reportable segments.
2. Segment profit is reconciled to operating profit as presented in the consolidated statement of income.

4. Matters regarding changes in reportable segments, etc.

The Group previously omitted segment information disclosure as it operated in a single segment, the Ishinkan business. However, starting from the current fiscal year, following a review of management control divisions, the Group has disclosed its reportable segments as "Ishinkan" and "Comprehensive Medical Support."

Segment information for the previous fiscal year is disclosed based on the revised reportable segment classifications.

(Per Share Information)

| | Fiscal year ended September 30, 2025 | Fiscal year ended September 30, 2026 |
|---|---|---|
| Net assets per share | 370.46 yen | 380.54 yen |
| Earnings per share | 37.52 yen | 13.05 yen |
| Diluted earnings per share | 37.51 yen | 13.04 yen |

(Note) The basis for calculating earnings per share is as follows.

| Item | Fiscal year ended September 30, 2025 | Fiscal year ended September 30, 2026 |
|---|---|---|
| Earnings per share | | |
| Profit attributable to owners of parent (million yen) | 3,660 | 1,277 |
| Profit not attributable to common shareholders (million yen) | — | — |
| Profit attributable to owners of parent attributable to common shareholders (million yen) | 3,660 | 1,277 |
| Average number of common shares outstanding during the period (shares) | 97,559,825 | 97,887,239 |
| Diluted earnings per share | | |
| Adjustment to profit attributable to owners of parent (million yen) | — | — |
| Increase in number of common shares (shares) | 13,661 | 13,134 |
| (Number of stock acquisition rights included in the increase) (shares) | (13,661) | (13,134) |
| Outline of potential common shares not included in the calculation of diluted earnings per share due to the absence of dilutive effect | — | 6th Series of Share Acquisition Rights: 5,000 rights (500,000 common shares)<br>7th Series of Share Acquisition Rights: 18,920 rights (1,892,000 common shares) |

2. The basis for calculating net assets per share is as follows.

| Item | As of September 30, 2025 | As of September 30, 2026 |
|---|---|---|
| Total net assets (million yen) | 36,132 | 37,386 |
| Amount to be deducted from total net assets (million yen) | — | 73 |
| (of which: stock acquisition rights) (million yen) | — | 73 |
| Net assets pertaining to common stock at the end of the period (million yen) | 36,132 | 37,313 |
| Number of shares of common stock used for the calculation of net assets per share at the end of the period (shares) | 97,533,843 | 98,053,143 |

(Significant Subsequent Events)

(Business Separation through Absorption-Type Company Splits and Transfers of Shares in Subsidiaries)

On September 28, 2026, the Company entered into a share transfer agreement to transfer the business relating to 47 Ishinkan facilities operated by the Group, primarily located in western Japan, to Amvis Holdings West, Inc. and Amvis West, Inc. through absorption-type company splits within the Group, and subsequently transfer all shares in both companies to NSSK-Altair 1 Co., Ltd.

The absorption-type company split in which the Company is the splitting company and the share transfers were approved at the extraordinary general meeting of shareholders held on November 13, 2026. The Company plans to transfer all shares in both companies to NSSK-Altair 1 Co., Ltd. on November 16, 2026.

1. Overview of the Business Separation through Company Splits and Share Transfers

(1) Names of the companies succeeding to the separated business through the company splits (absorption-type successor companies) and the transferee of the shares

(i) Names of the companies succeeding to the separated business through the company splits (absorption-type successor companies)

Amvis Holdings West, Inc. and Amvis West, Inc.

(ii) Name of the transferee of the shares

NSSK-Altair 1 Co., Ltd.

(2) Description of the separated business

The business relating to 47 Ishinkan facilities operated by Amvis, Inc., primarily located in western Japan, together with the assets, liabilities, contracts, and other rights and obligations held by the Company in connection with the business, as specified in the respective absorption-type company split agreements.

(3) Main reasons for the business separation

The Group determined that operating the subject business under NSSK (Nippon Sangyo Suishin Kiko) would be the optimal approach from the perspective of achieving sustainable growth in the hospice business in western Japan and enhancing corporate value over the medium to long term.

The transaction is also intended to enable the Group to concentrate its management resources on the Tokyo metropolitan area and eastern Japan, while strengthening its financial position and expanding its capacity for growth investments.

(4) Dates of the business separation

(i) Effective dates of the company splits

Absorption-type company split in which Amvis, Inc. is the splitting company: November 1, 2026

Absorption-type company split in which Amvis Holdings, Inc. is the splitting company: November 16, 2026 (scheduled)

(ii) Date of the share transfers

November 16, 2026 (scheduled)

(5) Other matters concerning the overview of the transactions, including their legal forms

(i) Company splits

An absorption-type company split in which the Company (Amvis Holdings, Inc.) is the splitting company and Amvis Holdings West, Inc. is the absorption-type successor company. In connection with this company split, the successor company plans to issue and allot 800 shares of its common stock to the Company.

In addition, an absorption-type company split in which Amvis, Inc. is the splitting company and Amvis West, Inc. is the absorption-type successor company. This company split will be conducted without consideration, and no shares, cash, or other consideration will be allotted.

(ii) Share transfers

The Group will transfer all shares it holds in Amvis Holdings West, Inc. and Amvis West, Inc. to NSSK-Altair 1 Co., Ltd.

The number of shares to be transferred will be 1,000 shares and 200 shares, respectively (representing 100% of the voting rights in each company). Following the transfers, the Group will hold no shares in either company.

The total transfer price for the two companies is expected to be 17,400 million yen.

2. Reportable Segment to Which the Separated Business Belonged

Ishinkan Business